The classical consideration of vitamin D as a regulator of calcium and phosphate metabolism and bone biology began to change in 1981, when David Feldman's and Tatsuo Suda's groups showed that the most active vitamin D metabolite 1 ,25-dihydroxyvitamin D 3 (1,25(OH) 2 D 3 , calcitriol) inhibited the proliferation of melanoma cells and induced the differentiation of leukemic cells [1, 2] . These seminal, pioneer findings opened a new era in the study of 1,25(OH) 2 D 3 , which is now seen as a hormone with pleiotropic effects in the organism.
A large number of epidemiological and experimental studies performed in cultured cells and animal models over the last thee decades support a cancer preventive and, perhaps, a therapeutic role for 1,25(OH) 2 D 3 and a series of synthetic vitamin D analogs [3, 4, reviews] .
The initial phase I and phase II cancer clinical studies showed acceptable toxicity but low activity of these compounds [5, review] . As is usual in the development of new antitumoral drugs, patients enrolled in these trials were not responding to any other therapy, and they were unselected in terms of putative responsiveness to vitamin D compounds. Recent data on the physiology of the vitamin D system improve our understanding of the action of 1,25(OH) 2 D 3 at the molecular and cellular level, which may in turn help us to design future clinical trials more rationally. In this chapter, we summarize current knowledge on the mechanisms that dictate the response or resistance to 1,25(OH) 2 [3, 5] .
In summary ( has paracrine and autocrine activity that may be involved in a defense mechanism against cancer progression [7, 8] inhibitors increased CYP27B1 expression [9] . One study has proposed that the mechanism of decreased CYP27B1 activity in prostate cancer cell lines is via decreased gene expression while in primary cultures and tissues it is post-translational [10] . Moreover, the finding that CYP27B1 is also present in tumor infiltrating macrophages suggests an immunomodulatory component of 1,25(OH) 2 D 3 production in some types of cancer [8] . Epithelial cells from gastrointestinal tract, breast, kidney, prostate, bladder and liver contain VDR. Moreover, VDR is expressed in bone, muscle and skin cells as well as some activated cells of the immune system [3] . Tumor cells derived from these tissues usually express VDR and maintain the capacity to respond to 1,25(OH) 2 D 3 . Remarkably, elevated VDR expression 7 is associated with high differentiation, absence of node involvement and favourable prognosis in colorectal cancer [18] [19] [20] , and with late development of lymph node metastases and longer disease-free survival in breast cancer [21, 22] . However, downregulation of VDR expression has been found in several tumors (colon, breast, lung…) compared with their corresponding normal tissue [7, 23] . In colon cancer, VDR expression is induced in the early stages of tumorigenesis (polyps and adenomas) and decreases during colon cancer progression [7] . However, their consequences for VDR expression or functionality, and therefore their implication in the development of 1,25(OH) 2 D 3 resistance remain to be established [24] .
A mechanism responsible for VDR downregulation, at least in colon cancer, has emerged in the last years. Our group has revealed that the transcription factor Snail1 binds to the human VDR gene promoter and represses its expression in human colon cancer cells. In addition, Snail1 also reduces VDR mRNA half-life [25] . Accordingly, overexpression of Snail1 in human colon cancer cells blocks the prodifferentiation action of 1,25(OH) 2 D 3 and its inhibitory effect on cell proliferation and migration. Snail1 also represses VDR expression and abrogates the antitumoral effect of EB1089 (a 1,25(OH) 2 D 3 analog) in xenografted mice (Fig. 2) [25, 26] . Upregulation of Snail1 has been found in approximately 60% of colon tumors and it has been significantly associated with diminished VDR expression [25, 27] .
These data indicate that Snail1 induction is probably responsible for VDR downregulation 8 during colon cancer progression and indicate that tumors with high Snail1 expression would be resistant to treatment with 1,25(OH) 2 D 3 or its analogs. Since Snail1 is up-regulated in advanced tumors (associated with acquisition of migratory and invasive properties), 1,25(OH) 2 D 3 and its analogs should preferentially be used as chemopreventive drugs, particularly for high risk patients, and as chemotherapeutic agents to be administered during the early stages of carcinogenesis [28] . In addition, as Snail1 up-regulation has been reported in cancers other than colon (synovial sarcoma and breast, gastric and hepatocellular carcinomas) [29, review] this mechanism could be responsible for VDR downregulation and vitamin D resistance in other tumors. It has also been shown that H-ras transformation of HC11 mammary cells or NIH 3T3 fibroblasts provokes a reduction of VDR mRNA levels leading to 1,25(OH) 2 D 3 resistance. In these cases, transcriptional repression was ruled out and VDR downregulation seemed to be due to a decrease in VDR mRNA stability [30, 31] . As the Ras-Raf-MAPK pathway is one of the inducers of Snail1 [29] , VDR downregulation by oncogenic H-ras is probably mediated by Snail1. Remarkably, ectopic VDR re-expression diminished H-ras-induced transformation in NIH 3T3 cells [31] .
Several studies have identified compounds that increase VDR expression and/or 1,25(OH) 2 17 -estradiol and certain phytoestrogens induce VDR and CYP27B1 expression while they reduce that of CYP24A1. Therefore, the treatment of tumors with estrogens would increase VDR levels and overcome the resistance to 1,25(OH) 2 D 3 analogs [32] . In addition, the transcription factor p53 and its family members p63 , p73 and p73 activate human VDR gene transcription. These transcription factors are activated in turn by genotoxic stresses such as certain chemotherapeutic drugs. It is therefore expected that combined treatment with 9 chemotherapy may enhance cell sensitivity to the antitumoral effects of 1,25(OH) 2 D 3 because the increase in the levels of p53 family members by chemotherapy could induce VDR [32] . 2 action [24] . Therefore, various groups began to examine whether epigenetic mechanisms were disrupting VDR signalling, and they found that these mechanisms caused decreased responsiveness to 1,25(OH) 2 D 3 in prostate and breast cancer [33] . This epigenetic corruption results from an abnormal pattern of expression of corepressors or coactivators. In addition, altered post-translational modifications of VDR or RXR may also diminish VDR transcriptional activity.
Resistance to 1,25(OH)
Elevated expression of the corepressors SMRT and NCoR has been reported in prostate and breast cancer cell lines, respectively [34, 35] . Moreover, an increased ratio of corepressor/VDR RNA is also observed in matched primary tumor and normal breast cells, particularly associated with estrogen receptor negativity [35] . This alteration causes resistance to the antiproliferative effect of 1,25(OH) 2 D 3 , which can be restored with inhibitors of histone deacetylases (trichostatin) and DNA methyltransferases (5-aza-2'-deoxycytidine) [34] [35] [36] . This also explains the synergistic inhibitory effect of combined treatment with 1,25(OH) 2 D 3 and sodium butyrate or trichostatin on the proliferation of prostate cancer cells [37] . The abnormal expression of coregulators may explain why VDR content does not predict the antiproliferative effects of 1,25(OH) 2 D 3 in some cancer cells [24] . Interestingly, in line with the increasing tendency to consider stroma as a critical regulator of tumor progression, altered VDR-mediated transcriptional activity due to abnormal VDR DNA binding and SMRT recruitment has been described in prostate cancer stroma [38] . 
